AROMASIN® Tablets for oral administration contain 25 mg of exemestane, an irreversible, steroidal aromatase inactivator.
AROMASIN Tablets are indicated for the treatment of advanced breast cancer in postmenopausal women whose disease has progressed following tamoxifen therapy.
Media Articles Related to Aromasin (Exemestane)
Breast Cancer Timeline: Quiet 100 Years and Then Boom
Source: Medscape General Surgery Headlines [2015.01.29]
A timeline of developments in the treatment of breast cancer reveals great change in the past 20 to 30 years, according to two experts.
Medscape Medical News
Mayo Clinic: New breast cancer risk prediction model more accurate than current model
Source: Breast Cancer News From Medical News Today [2015.01.28]
A new breast cancer risk prediction model combining histologic features of biopsied breast tissue from women with benign breast disease and individual patient demographic information more accurately...
Lung cancer to overtake breast cancer as most fatal among European women
Source: Breast Cancer News From Medical News Today [2015.01.28]
Predictions for 2015 estimate that, for the first time, the death rates for lung cancer among women in Europe will exceed those for breast cancer.
Death rates from lung cancer will overtake those for breast cancer in 2015 among EU women
Source: Lung Cancer News From Medical News Today [2015.01.28]
Death rates from lung cancer will exceed those for breast cancer for the first time among European women in 2015, according to the latest predictions published in the leading cancer journal Annals of...
New breast exam nearly quadruples detection of invasive breast cancers in women with dense breast tissue
Source: Breast Cancer News From Medical News Today [2015.01.27]
A new breast imaging technique pioneered at Mayo Clinic nearly quadruples detection rates of invasive breast cancers in women with dense breast tissue, according to the results of a major study...
Published Studies Related to Aromasin (Exemestane)
Everolimus plus exemestane in postmenopausal patients with HR(+) breast cancer:
BOLERO-2 final progression-free survival analysis. 
this patient population... CONCLUSION: The addition of everolimus to exemestane markedly prolonged PFS in
Randomized phase II, double-blind, placebo-controlled study of exemestane with or
without entinostat in postmenopausal women with locally recurrent or metastatic
estrogen receptor-positive breast cancer progressing on treatment with a
nonsteroidal aromatase inhibitor. 
alone... CONCLUSION: Entinostat added to exemestane is generally well tolerated and
Health-related quality of life of patients with advanced breast cancer treated
with everolimus plus exemestane versus placebo plus exemestane in the phase 3,
randomized, controlled, BOLERO-2 trial. 
(HRQOL)... CONCLUSIONS: In patients with advanced breast cancer who develop disease
Ganitumab with either exemestane or fulvestrant for postmenopausal women with
advanced, hormone-receptor-positive breast cancer: a randomised, controlled,
double-blind, phase 2 trial. 
hormone-receptor-positive breast cancer... INTERPRETATION: Addition of ganitumab to endocrine treatment in women with
Bone density and structure in healthy postmenopausal women treated with
exemestane for the primary prevention of breast cancer: a nested substudy of the
MAP.3 randomised controlled trial. 
of potential widespread use, we examined the safety of exemestane on bone health... INTERPRETATION: 2 years of treatment with exemestane worsens age-related bone
Clinical Trials Related to Aromasin (Exemestane)
Exemestane As Treatment In Adjuvant For Post-Menopausal Patients With Non-Metastatic Breast Cancer [Active, not recruiting]
To compare recurrence free survival between two treatment groups (5 years with exemestane vs
2. 5 to 3 years tamoxifen followed by 2 to 2. 5 years of exemestane for a total duration of 5
Open Label, Multicenter, Randomized, Controlled Study of IM or Oral Exemestane (Aromasin) in Postmenopausal Women [Terminated]
The purpose of this study is to find out if the two different formulations of exemestane
(Aromasin), oral and injectable, are equivalent in terms of pharmacodynamics and
pharmacokinetics, i. e., if ultimately both formulations have the same efficacy in
postmenopausal women with metastatic breast cancer who have failed previous antiestrogens
therapy and are equally safe.
An Observational Study Of Indian Breast Cancer Patients Receiving Adjuvant Therapy With Aromasin [Recruiting]
To generate the following data from patients with early breast cancer treated with Aromasin®
in the adjuvant setting in India.
- Efficacy of the treatment with Aromasin®
- Safety of the treatment with Aromasin®
The Evaluation of the Efficacy and Tolerability of FASLODEX (Fulvestrant) and AROMASIN (Exemestane) in Hormone Receptor Positive Postmenopausal Women With Advanced Breast Cancer [Active, not recruiting]
The purpose of this study is to compare the efficacy of Faslodex (fulvestrant) to Aromasin
(exemestane) in hormone receptor positive postmenopausal women with advanced breast cancer.
Patients will be treated until disease progression or until the investigator has determined
that treatment is not in the best interest of the patient, whichever occurs first.
Safety and Efficacy of AZD4547 in Combination With Fulvestrant vs. Fulvestrant Alone in ER+ Breast Cancer Patients [Recruiting]
The purpose of this study is to assess the safety and effectiveness of AZD4547 in
combination with fulvestrant vs. fulvestrant alone in ER+ breast cancer patients with FGFR1
polysomy (FISH4/5) or gene amplification (FISH 6)
Reports of Suspected Aromasin (Exemestane) Side Effects
Disease Progression (19),
Breast Cancer (18),
Abdominal Distension (12),
Bone Pain (11),
Headache (11), more >>
PATIENT REVIEWS / RATINGS / COMMENTS
Based on a total of 2 ratings/reviews, Aromasin has an overall score of 8.50. The effectiveness score is 9 and the side effect score is 8. The scores are on ten point scale: 10 - best, 1 - worst.
Aromasin review by 57 year old female patient
|Overall rating:|| || |
|Effectiveness:|| || Considerably Effective|
|Side effects:|| || No Side Effects|
|Condition / reason:|| || Breast Cancer|
|Dosage & duration:|| || 5mg taken 1/day for the period of 3 years|
|Other conditions:|| || under-active thyroid|
|Other drugs taken:|| || Synthroid|
|Benefits:|| || Aromasin's treatment benefits are unknown. I have not had a reoccurance of breast cancer while on the drug, though unsure we can attribute that with the drug treatment itself. Perhaps there are other positive health-related items coming into play, such as exerciase and eating habits. Not aware of any side effects or adverse reactions. Drug is very expensive, however. |
|Side effects:|| || As mentioned above, I have not had any side effects from Aromasin other than hot flashes and night sweats. These may be due to menopause rather than the treatment itself. The hot flashes have been relatively mild and can be controlled, for the most part, by limiting or removing all alcoholic beverages. |
|Comments:|| || After breast cancer treatment of chemo. and radiation I was put on Tamoxifen for several years, about 5 years. After Tamoxifen, it was recommended that I start taking Aromasin, which I have done for about 3 years. My doctor said it is not known how long women should be on Aromasin and still receeve a benefit from taking the drug.|
Aromasin review by 58 year old female patient
|Overall rating:|| || |
|Effectiveness:|| || Highly Effective|
|Side effects:|| || Moderate Side Effects|
|Condition / reason:|| || eostrogen-positive breast cancer|
|Dosage & duration:|| || 25mg taken daily for the period of 4 years|
|Other conditions:|| || high blood pressure|
|Other drugs taken:|| || various blood pressure medications|
|Benefits:|| || During the 4 years so far [out of 5], I have had no recurrance of the tumour and no additional tumours have been detected by ultra-sound, mammogram, and twice-yearly check-ups. Perhaps the greatest benefit is the gradual reduction in stress experienced as a result of my on-going stabilised condition after a lumpectomy.|
|Side effects:|| || I had some initial swelling of my hip, knee and ankle joints in the morning which slowly subsided during the day. The medication also aggravated the hot-flushes of the menopause, making them initially frequent and copious, and on-going for the treatment duration so far - tho with reduced frequency now in Year 4. I also experience considerable thirst.|
|Comments:|| || I was put on Aromasin after 6 months on Tamoxifen because I suffered debilitating muscle cramps on Tamoxifen as well as joint problems and extreme hot flushes. Aromasin has been kinder, and so far I have taken it daily for 4 years out of an initial 5. It may be prescribed beyond 5 years, I'm not sure. It has relatively slight side effects now but in the first 6 months I was conscious of its effects on my body - not intolerable by any means, just noticable.|
Page last updated: 2015-01-29